Empowered Funds LLC Buys 49,874 Shares of DaVita Inc. (NYSE:DVA)

Empowered Funds LLC increased its stake in DaVita Inc. (NYSE:DVA) by 856.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,698 shares of the company’s stock after acquiring an additional 49,874 shares during the quarter. Empowered Funds LLC owned about 0.07% of DaVita worth $8,330,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Transcendent Capital Group LLC acquired a new stake in DaVita during the 3rd quarter worth about $25,000. Blue Trust Inc. increased its stake in shares of DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Quarry LP bought a new position in DaVita during the third quarter worth $60,000. Versant Capital Management Inc grew its holdings in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after purchasing an additional 169 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in DaVita in the third quarter valued at $97,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 0.8 %

DaVita stock opened at $173.45 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm’s fifty day moving average price is $160.59 and its two-hundred day moving average price is $156.53. The firm has a market capitalization of $14.22 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94. DaVita Inc. has a 1-year low of $108.76 and a 1-year high of $179.60.

Analyst Upgrades and Downgrades

Separately, Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.